Aperio Group LLC raised its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 99.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 28,823 shares of the biopharmaceutical company’s stock after buying an additional 14,353 shares during the period. Aperio Group LLC’s holdings in Halozyme Therapeutics were worth $370,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in the stock. Ameritas Investment Partners Inc. acquired a new stake in shares of Halozyme Therapeutics during the first quarter valued at about $122,000. Karp Capital Management Corp acquired a new stake in shares of Halozyme Therapeutics during the first quarter valued at about $188,000. Stifel Financial Corp acquired a new stake in shares of Halozyme Therapeutics during the first quarter valued at about $187,000. Principal Financial Group Inc. increased its stake in shares of Halozyme Therapeutics by 2.8% in the first quarter. Principal Financial Group Inc. now owns 20,602 shares of the biopharmaceutical company’s stock valued at $267,000 after buying an additional 558 shares in the last quarter. Finally, Paloma Partners Management Co acquired a new stake in shares of Halozyme Therapeutics during the first quarter valued at about $268,000. 85.08% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics, Inc. (HALO) traded down 0.86% on Wednesday, reaching $12.62. The company’s stock had a trading volume of 291,310 shares. The firm’s market cap is $1.69 billion. The firm has a 50 day moving average of $12.72 and a 200 day moving average of $13.14. Halozyme Therapeutics, Inc. has a 12 month low of $8.18 and a 12 month high of $15.20.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.02. The business had revenue of $33.80 million during the quarter, compared to analysts’ expectations of $31.76 million. During the same quarter in the previous year, the firm earned ($0.21) earnings per share. Halozyme Therapeutics’s revenue was up 1.2% on a year-over-year basis. Analysts anticipate that Halozyme Therapeutics, Inc. will post ($0.97) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this report on another domain, it was copied illegally and republished in violation of US & international trademark and copyright laws. The legal version of this report can be accessed at https://www.watchlistnews.com/aperio-group-llc-raises-position-in-halozyme-therapeutics-inc-halo/1532281.html.

Several equities research analysts have issued reports on the company. Zacks Investment Research raised Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a report on Friday, August 25th. Piper Jaffray Companies set a $20.00 price target on Halozyme Therapeutics and gave the company a “buy” rating in a report on Thursday, August 10th. BidaskClub downgraded Halozyme Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, August 18th. Jefferies Group LLC reaffirmed an “underperform” rating and set a $7.00 price target (up previously from $6.75) on shares of Halozyme Therapeutics in a report on Thursday, August 10th. Finally, Canaccord Genuity set a $16.00 price target on Halozyme Therapeutics and gave the company a “buy” rating in a report on Wednesday, July 26th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $14.75.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.